Louisiana State Employees Retirement System Increases Position in Johnson & Johnson (NYSE:JNJ)

Louisiana State Employees Retirement System lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 113,300 shares of the company’s stock after purchasing an additional 1,400 shares during the quarter. Johnson & Johnson accounts for 1.0% of Louisiana State Employees Retirement System’s portfolio, making the stock its 7th largest position. Louisiana State Employees Retirement System’s holdings in Johnson & Johnson were worth $15,933,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Geode Capital Management LLC boosted its position in shares of Johnson & Johnson by 1.5% during the first quarter. Geode Capital Management LLC now owns 38,965,156 shares of the company’s stock worth $5,100,421,000 after purchasing an additional 572,077 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Johnson & Johnson by 3.2% during the fourth quarter. Bank of New York Mellon Corp now owns 32,846,195 shares of the company’s stock worth $4,791,274,000 after acquiring an additional 1,021,877 shares during the period. Wellington Management Group LLP raised its holdings in shares of Johnson & Johnson by 10.8% during the first quarter. Wellington Management Group LLP now owns 30,556,662 shares of the company’s stock worth $4,006,895,000 after acquiring an additional 2,968,879 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in shares of Johnson & Johnson by 7.7% during the first quarter. Massachusetts Financial Services Co. MA now owns 29,526,058 shares of the company’s stock worth $3,871,753,000 after acquiring an additional 2,118,870 shares during the period. Finally, Norges Bank acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $4,139,107,000. 68.44% of the stock is currently owned by institutional investors.

A number of equities research analysts recently commented on the stock. Bank of America upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $150.00 to $175.00 in a report on Wednesday, April 22nd. Argus restated a “buy” rating and set a $155.00 price objective (down from $165.00) on shares of Johnson & Johnson in a report on Friday, March 27th. UBS Group lowered shares of Johnson & Johnson from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $163.00 to $160.00 in a report on Tuesday, April 28th. Raymond James raised their price objective on shares of Johnson & Johnson from $153.00 to $157.00 and gave the stock an “outperform” rating in a report on Wednesday, April 15th. Finally, SVB Leerink lowered their price target on shares of Johnson & Johnson from $172.00 to $160.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 8th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and twelve have assigned a buy rating to the company. Johnson & Johnson presently has an average rating of “Buy” and an average target price of $162.93.

Shares of JNJ opened at $145.21 on Tuesday. The company has a market cap of $375.09 billion, a PE ratio of 19.21, a price-to-earnings-growth ratio of 3.10 and a beta of 0.69. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.31 and a quick ratio of 1.05. The firm has a 50-day moving average of $143.57 and a 200-day moving average of $143.88. Johnson & Johnson has a one year low of $109.16 and a one year high of $157.00.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 14th. The company reported $2.30 EPS for the quarter, topping the consensus estimate of $2.03 by $0.27. The business had revenue of $20.69 billion during the quarter, compared to the consensus estimate of $19.48 billion. Johnson & Johnson had a net margin of 24.47% and a return on equity of 39.71%. Johnson & Johnson’s revenue was up 3.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.10 EPS. Analysts expect that Johnson & Johnson will post 7.7 earnings per share for the current year.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: What does a bar chart display?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.